Do p53 stress responses impact organismal aging?

p53 is a transcriptional regulator that responds to cellular stresses to suppress oncogenesis, but some of these responses can have unintended consequences that influence non-cancer-related aging processes. The impact of these consequences is not well understood-partly due to the many complex processes that influence p53 function and partly due to the vast array of processes that p53 affects. p53 has the potential to both accelerate and hinder cellular aging processes, which would likely have antithetical biological outcomes with regard to organismal aging. To accelerate aging, p53 induces apoptosis or cell cycle arrest as a prerequisite to cellular senescence; both can impair the mobilization of stem and progenitor cell populations. To suppress aging, p53 inhibits unregulated proliferation pathways that could lead to cellular senescence and a senescence-associated secretory phenotype (SASP), which creates a pro-inflammatory and degenerative tissue milieu. A review of mouse models supports both possibilities, highlighting the complexity of the p53 influence over organismal aging. A deeper knowledge of how p53 integrates and is integrated with various biological processes will improve our understanding of its influence over the aging process.

[1]  C. Livi,et al.  p53 and rapamycin are additive , 2015, Oncotarget.

[2]  W. Gu,et al.  Ferroptosis as a p53-mediated activity during tumour suppression , 2015, Nature.

[3]  V. Marcel,et al.  p53, a translational regulator: contribution to its tumour-suppressor activity , 2015, Oncogene.

[4]  E. Reiling,et al.  The Progeroid Phenotype of Ku80 Deficiency Is Dominant over DNA-PKCS Deficiency , 2014, PloS one.

[5]  Z. D. Sharp,et al.  Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction , 2014, Aging cell.

[6]  S. Austad,et al.  Rapamycin extends life and health in C57BL/6 mice. , 2014, The journals of gerontology. Series A, Biological sciences and medical sciences.

[7]  C. Livi,et al.  eRapa Restores a Normal Life Span in a FAP Mouse Model , 2013, Cancer Prevention Research.

[8]  L. Donehower,et al.  REGγ deficiency promotes premature aging via the casein kinase 1 pathway , 2013, Proceedings of the National Academy of Sciences.

[9]  C. Livi,et al.  Rapamycin extends life span of Rb1+/− mice by inhibiting neuroendocrine tumors , 2013, Aging.

[10]  P. Hasty,et al.  p53 as an intervention target for cancer and aging , 2013, Pathobiology of aging & age related diseases.

[11]  S. Austad,et al.  Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice , 2012, Neuroscience.

[12]  M. Antoch,et al.  New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53−/− mice by delaying carcinogenesis , 2012, Aging.

[13]  J. M. Villalba,et al.  Sirtuin activators and inhibitors , 2012, BioFactors.

[14]  Hong Wu,et al.  A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. , 2012, Cancer cell.

[15]  M. Blagosklonny.  Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression? , 2012, Aging.

[16]  D. Sabatini,et al.  mTOR Signaling in Growth Control and Disease , 2012, Cell.

[17]  A. Bartke,et al.  Rapamycin slows aging in mice , 2012, Cell cycle.

[18]  Stephen N. Jones,et al.  Mdm2-p53 signaling regulates epidermal stem cell senescence and premature aging phenotypes in mouse skin. , 2011, Developmental biology.

[19]  R. de Cabo,et al.  Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. , 2011, The journals of gerontology. Series A, Biological sciences and medical sciences.

[20]  Karen H. Vousden,et al.  p53 and its mutants in tumor cell migration and invasion , 2011, The Journal of cell biology.

[21]  F. Gage,et al.  Puma is required for p53-induced depletion of adult stem cells , 2010, Nature Cell Biology.

[22]  Di Chen,et al.  With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. , 2010, Cell metabolism.

[23]  A. Gudkov,et al.  The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway , 2010, Aging.

[24]  A. Gudkov,et al.  Paradoxical suppression of cellular senescence by p53 , 2010, Proceedings of the National Academy of Sciences.

[25]  Scott W. Lowe,et al.  Stem cells: The promises and perils of p53 , 2009, Nature.

[26]  H. Vogel,et al.  Unlike p53, p27 failed to exhibit an anti-tumor genetic interaction with Ku80 , 2009, Cell cycle.

[27]  Marco Pahor,et al.  Rapamycin fed late in life extends lifespan in genetically heterogeneous mice , 2009, Nature.

[28]  C. Prives,et al.  Blinded by the Light: The Growing Complexity of p53 , 2009, Cell.

[29]  Jan Vijg,et al.  Ku80 deletion suppresses spontaneous tumors and induces a p53-mediated DNA damage response. , 2008, Cancer research.

[30]  Shaomeng Wang,et al.  Targeting the MDM2-p53 Interaction for Cancer Therapy , 2008, Clinical Cancer Research.

[31]  P. Hasty,et al.  DNA double-strand breaks: A potential causative factor for mammalian aging? , 2008, Mechanisms of Ageing and Development.

[32]  S. Bojesen,et al.  The common germline Arg72Pro polymorphism of p53 and increased longevity in humans , 2008, Cell cycle.

[33]  H. K. Sluss,et al.  The ataxia telangiectasia-mutated target site Ser18 is required for p53-mediated tumor suppression. , 2007, Cancer research.

[34]  L. Donehower,et al.  Aging-associated truncated form of p53 interacts with wild-type p53 and alters p53 stability, localization, and activity , 2007, Mechanisms of Ageing and Development.

[35]  H. Vogel,et al.  Deletion of Ku70, Ku80, or Both Causes Early Aging without Substantially Increased Cancer , 2007, Molecular and Cellular Biology.

[36]  P. Klatt,et al.  Delayed ageing through damage protection by the Arf/p53 pathway , 2007, Nature.

[37]  A. Levine,et al.  The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. , 2007, Cancer research.

[38]  L. Donehower,et al.  The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. , 2007, Blood.

[39]  C. Tsang,et al.  Targeting mammalian target of rapamycin (mTOR) for health and diseases. , 2007, Drug discovery today.

[40]  P. Puigserver,et al.  Resveratrol improves health and survival of mice on a high-calorie diet , 2006, Nature.

[41]  D. Sabatini,et al.  Stress and mTORture signaling , 2006, Oncogene.

[42]  D. Lane,et al.  p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress , 2006, Cell Death and Differentiation.

[43]  G. Wahl,et al.  A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. , 2006, Cancer cell.

[44]  G. Lozano,et al.  Tissue-Specific Differences of p53 Inhibition by Mdm2 and Mdm4 , 2006, Molecular and Cellular Biology.

[45]  W. Deppert,et al.  Transcription-independent pro-apoptotic functions of p53. , 2005, Current opinion in cell biology.

[46]  David P Lane,et al.  p53 isoforms can regulate p53 transcriptional activity. , 2005, Genes & development.

[47]  Bernd W. Brandt,et al.  Variation in the human TP53 gene affects old age survival and cancer mortality1 , 2005, Experimental Gerontology.

[48]  J. Wood,et al.  Sirtuin activators mimic caloric restriction and delay ageing in metazoans , 2004, Nature.

[49]  Myriam Gorospe,et al.  Calorie Restriction Promotes Mammalian Cell Survival by Inducing the SIRT1 Deacetylase , 2004, Science.

[50]  Stuart Tyner,et al.  Insights into Aging Obtained from p53 Mutant Mouse Models , 2004, Annals of the New York Academy of Sciences.

[51]  K. Mohammad,et al.  Modulation of mammalian life span by the short isoform of p53. , 2004, Genes & development.

[52]  S. Korsmeyer,et al.  Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. , 2003, Cancer research.

[53]  J. Hoeijmakers,et al.  Aging and Genome Maintenance: Lessons from the Mouse? , 2003, Science.

[54]  M. Murphy,et al.  The codon 72 polymorphic variants of p53 have markedly different apoptotic potential , 2003, Nature Genetics.

[55]  C. Deng,et al.  Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 full-length isoform. , 2003, Genes & development.

[56]  Muyang Li,et al.  Acetylation of p53 Inhibits Its Ubiquitination by Mdm2* , 2002, The Journal of Biological Chemistry.

[57]  P. Klatt,et al.  'Super p53' mice exhibit enhanced DNA damage response, are tumor resistant and age normally , 2002, The EMBO journal.

[58]  Yili Yin,et al.  p53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products , 2002, Nature Cell Biology.

[59]  Stephen N. Jones,et al.  p53 mutant mice that display early ageing-associated phenotypes , 2002, Nature.

[60]  Valerie Reinke,et al.  Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53 , 2001, Nature Genetics.

[61]  Curtis C. Harris,et al.  Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis , 2001, Nature Genetics.

[62]  L. Donehower,et al.  Is p53 Haploinsufficient for Tumor Suppression? Implications for the p53+/- Mouse Model in Carcinogenicity Testing , 2001, Toxicologic pathology.

[63]  Lawrence A. Donehower,et al.  The Nature of the Heterozygous Trp53 Knockout Model for Identifi cation of Mutagenic Carcinogens , 2001, Toxicologic pathology.

[64]  H. Vogel,et al.  Analysis of ku80-Mutant Mice and Cells with Deficient Levels of p53 , 2000, Molecular and Cellular Biology.

[65]  H. Vogel,et al.  Deletion of Ku86 causes early onset of senescence in mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[66]  Kevin Ryan,et al.  The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 , 1998, The EMBO journal.

[67]  D. Pinkel,et al.  Retention of wild‐type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation , 1998, The EMBO journal.

[68]  F. Zindy,et al.  Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[69]  E. Masoro.  Influence of caloric intake on aging and on the response to stressors. , 1998, Journal of toxicology and environmental health. Part B, Critical reviews.

[70]  B. Fontoura,et al.  Cytoplasmic p53 polypeptide is associated with ribosomes , 1997, Molecular and cellular biology.

[71]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[72]  Guillermina Lozano,et al.  Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.

[73]  Lawrence A. Donehower,et al.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 , 1995, Nature.

[74]  L. Donehower,et al.  Effects of genetic background on tumorigenesis in p53‐deficient mice , 1995, Molecular carcinogenesis.

[75]  T. Jacks,et al.  A subset of p53-deficient embryos exhibit exencephaly , 1995, Nature Genetics.

[76]  V. Berlin,et al.  RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[77]  Stuart L. Schreiber,et al.  A mammalian protein targeted by G1-arresting rapamycin–receptor complex , 1994, Nature.

[78]  L. Donehower,et al.  Spontaneous and carcinogen–induced tumorigenesis in p53–deficient mice , 1993, Nature Genetics.

[79]  M. Mclaughlin,et al.  The tyrosine89 residue of yeast FKBP12 is required for rapamycin binding. , 1993, Gene.

[80]  L. Donehower,et al.  Genetic background alters the spectrum of tumors that develop in p53‐deficient mice , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[81]  B. Fontoura,et al.  p53 is covalently linked to 5.8S rRNA , 1992, Molecular and cellular biology.

[82]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[83]  Hiroshi I. Suzuki,et al.  p53 actions on microRNA expression and maturation pathway. , 2013, Methods in molecular biology.

[84]  D. Lane,et al.  Reactivation of p53: from peptides to small molecules. , 2011, Trends in pharmacological sciences.

[85]  Michael Karin,et al.  p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling , 2009, Cell.

[86]  R. Eisenman,et al.  Tumor suppression and normal aging in mice with constitutively high p53 activity. , 2006, Genes & development.

[87]  H. Scrable,et al.  DeltaNp53 or p44: priming the p53 pump. , 2005, The international journal of biochemistry & cell biology.

[88]  C. Harris,et al.  p53: traffic cop at the crossroads of DNA repair and recombination , 2005, Nature Reviews Molecular Cell Biology.